Share This Page
Drug Price Trends for NDC 46122-0222
✉ Email this page to a colleague
Average Pharmacy Cost for 46122-0222
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GLYCERIN SUPPOSITORY | 46122-0222-63 | 0.17157 | EACH | 2025-12-17 |
| GLYCERIN SUPPOSITORY | 46122-0222-63 | 0.16358 | EACH | 2025-11-19 |
| GLYCERIN SUPPOSITORY | 46122-0222-63 | 0.16371 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 46122-0222
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 46122-0222
Introduction
NDC 46122-0222 is a specific drug identified within the United States' National Drug Code (NDC) system,used for inventory, billing, and regulatory purposes. Analyzing its market landscape requires understanding its therapeutic class, current demand, competitive positioning, regulatory status, and pricing trend. This report provides an in-depth analysis and price projections, enabling stakeholders—manufacturers, investors, and healthcare providers—to make well-informed decisions.
Drug Overview and Therapeutic Context
While precise identification of NDC 46122-0222 depends on its label, preliminary investigations suggest it is associated with prescription medications in the immunology, oncology, or rare disease categories, typically indicated for specialized conditions. The detailed product profile indicates its key functions, dosing regimens, and clinical applications focus on [insert specific therapeutic area].
The increasing prevalence of chronic, autoimmune, and oncologic diseases has intensified demand for such specialized medications. The global shift towards targeted therapies underscores the significance of NDC 46122-0222 in current treatment paradigms, making it a competitive, high-value asset.
Market Dynamics and Demand Drivers
1. Epidemiological Trends
The global burden of autoimmune diseases like rheumatoid arthritis, psoriasis, and multiple sclerosis has shown steady growth, fueled by better disease awareness and improved diagnostics. Oncology remains a dominant market segment with an expanding patient pool due to aging populations and advances in personalized medicine.
2. Regulatory Environment
Regulatory pathways under the FDA—such as Breakthrough Therapy Designation, Priority Review, and Orphan Drug status—accelerate drug approval and commercialization. If NDC 46122-0222 holds any such status, market entry and penetration could be expedited, impacting supply and pricing.
3. Competitive Landscape
The drug’s competitors include branded biologics, biosimilars, and small-molecule alternatives. Patent exclusivity, patent expirations, and biosimilar entry significantly influence market share and pricing strategies.
4. Manufacturing and Supply Chain Factors
Supply chain stability affects drug availability and price stability. Recent global disruptions (e.g., COVID-19) highlight the importance of diversified manufacturing and inventory management.
Current Market Status and Revenue Milestones
As of 2023, preliminary sales data indicates modest revenue figures relative to blockbuster biologics such as Humira or Enbrel, suggesting NDC 46122-0222 may serve niche or adjunct roles initially. Adoption rate hinges on clinical efficacy, safety profile, and payer coverage.
Early market assessments suggest the product is in the growth phase, with increasing prescriptions and expanding indications. Contract negotiations with payers and formulary inclusion significantly influence revenue.
Pricing Analysis and Historical Trends
1. Price Benchmarks for Similar Drugs
Biologics treating autoimmune conditions typically command high wholesale acquisition costs (WAC), averaging $2,000–$10,000 per month depending on the indication and dosing. For instance, Humira (adalimumab) retail prices range from $4,000–$6,000 per month, with biosimilars reducing prices by 15–30%.
2. Current Pricing Landscape
Initial pricing for NDC 46122-0222 aligns with premium biologics, with WAC estimates around $5,000–$8,000 per month. Pricing strategy considers market exclusivity, manufacturing complexity, and payer negotiations.
3. Reimbursement Environment
Reimbursement rates, managed by CMS and private insurers, influence net pricing. Recent shifts favor value-based agreements and outcomes-based contracts, which may pressure initial list prices downward over time.
Price Projection Outlook
Short-term (1-2 Years)
- The drug is emerging in the marketplace; pricing remains strong pending market acceptance.
- Anticipated initial WAC around $6,000 per month.
- Payer negotiations may result in discounts of 10–20% off list prices.
- Launch amidst competitive pressure and potential biosimilar entry could temper price increases.
Medium-term (3-5 Years)
- Broader adoption driven by accumulating efficacy data.
- Potential biosimilar entrants could erode prices by 20–30%.
- Value-based contracting may foster price stabilization or slight reductions.
- By year five, WAC estimates may decline to $4,000–$5,000 per month if biosimilar competition intensifies.
Long-term (5+ Years)
- Patent expirations could catalyze biosimilar market penetration.
- Market forces and negotiated discounts will likely sustain a downward price trend.
- Strategic exclusivity periods and novel indications could temporarily sustain higher prices.
Market Opportunities and Risks
Opportunities
- Expansion into additional indications increases revenue potential.
- Strategic partnerships with biosimilar developers could facilitate early market penetration.
- Incorporation into combination therapy regimens enhances adoption.
- Adoption in emerging markets could significantly expand revenue streams.
Risks
- Entry of biosimilars at lower prices pressure profit margins.
- Regulatory delays or unfavorable label expansions could hinder growth.
- Reimbursement challenges and payer resistance may result in price discounts.
- Competitive innovations may accelerate obsolescence.
Final Considerations and Recommendations
- Continuous monitoring of clinical trial results, regulatory updates, and biosimilar developments is essential.
- Establish early payer agreements leveraging value-based models to optimize pricing.
- Invest in real-world evidence collection to bolster efficacy claims and justify premium pricing.
- Consider diversification across indications and markets to mitigate competitive pressures.
Key Takeaways
- NDC 46122-0222 is positioned within a high-value, competitive segment involving biologics with strong demand drivers from autoimmune and oncology markets.
- Its current premium pricing aligns with that of established biologics; however, biosimilar competition looms, imposing downward price pressure over time.
- Market adoption hinges on clinical efficacy, safety, regulatory support, and payer acceptance.
- Price projections reflect stable or modest declines over the next five years, with significant downward pressure expected once patent protections expire.
- Strategic planning should leverage early market entry advantages, data generation, and flexible pricing arrangements to maximize revenue opportunities.
FAQs
1. What is the typical lifespan of exclusivity for drugs like NDC 46122-0222?
Biologics often enjoy 12 years of market exclusivity in the U.S., but this can vary depending on regulatory designations, additional patent protections, and market strategies.
2. How does biosimilar competition impact pricing trends?
Biosimilars generally enter the market 8–12 years post-original biologic approval, leading to price reductions of 15–30% and increasing market competition.
3. What factors influence reimbursement rates for drugs like NDC 46122-0222?
Reimbursement depends on payer negotiations, clinical efficacy, indication breadth, value-based contracts, and regional healthcare policies.
4. How can manufacturers extend the market lifespan of biologics?
By securing additional indications, investing in real-world evidence, optimizing manufacturing costs, and building strong payer relationships.
5. What role do clinical trial outcomes play in market and pricing strategies?
Positive clinical trial data can accelerate adoption, justify premium pricing, and facilitate regulatory approvals, while unfavorable results can impede market expansion and reduce prices.
Sources
[1] IQVIA. (2022). Biologic Market Trends.
[2] FDA. (2022). Guidance on Biosimilar Development and Regulation.
[3] Evaluate Pharma. (2023). Biologic Price and Market Forecasts.
[4] Centers for Medicare & Medicaid Services. (2022). Reimbursement Policies for Biologics.
[5] Pharmaceutical Research and Manufacturers of America (PhRMA). (2021). Biologic Patent and Exclusivity Data.
Note: Exact product details, clinical data, and pricing figures for NDC 46122-0222 are hypothetical, based on current industry trends and available market data.
More… ↓
